FENC announced an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI in Europe, Australia, and New Zealand. PEDMARQSI is an approved therapy in the EU and U.K. for the prevention of ototoxicity (hearing loss) induced by cispl...查看全文
薛定锷之猫2023-02-01 00:20
$Fennec制药(FENC)$ 会有公司收购它吗?If yes,收购价会是多少呢?
Part I:
1、 PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid ...查看全文
美股律师郝俊波2022-02-11 15:14
$Fennec制药(FENC)$ 【Fennec制药(FENC)最新证券集体诉讼】
Fennec Pharmaceuticals Inc(FENC)因证券欺诈案已经于近日被投资者集体诉讼至法院。在目前的诉讼中投资者指控该公司在2021年5月28日至 2021年11月26日期间(即本案集体诉讼期间)进行虚假陈述,违反证券法,令投资者受损。
Fenn...查看全文
chuminhua2021-11-30 10:47
11月29日,Fennec Pharmaceuticals 的股价周一下跌多达 48%,此前该公司表示预计将收到另一封针对其化疗引起的听力损失预防药物的完整回复函 (CRL)。 Fennec 正在寻求批准其名为 Pedmark 的硫代硫酸钠静脉制剂,以防止 1 个月至 18 岁的局部非转移性实体瘤患者与顺铂化疗相关的耳毒性。
根据 F...查看全文
美股律师郝俊波2020-08-18 11:29
$Fennec制药(FENC)$ 2020年8月11日Fennec Pharmaceuticals Inc(NASDAQ: FENC)发布消息称收到美国药监局关于该公司正在申请上市的PEDMARK产品的调查函。该函中称药监局在对该产品评估后认为存在需要解决的问题。受此不利消息影响,该公司股价大跌34%令投资者受损。
我们律师在此提醒投资者注意...查看全文
$Fennec制药(FENC)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-22-109063 Act: 34 Size: 238 KB 网页链接
$Fennec制药(FENC)$ 8-K Current report, items 1.01, 2.03, 3.02, 8.01, and 9.01 Accession Number: 0001558370-22-014629 Act: 34 Size: 854 KB 网页链接
$Fennec制药(FENC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-22-009828 Size: 6 KB 网页链接
$Fennec制药(FENC)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-22-101910 Act: 34 Size: 240 KB 网页链接
$Fennec制药(FENC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-22-009516 Size: 5 KB 网页链接
$Fennec制药(FENC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-22-093721 Size: 5 KB 网页链接
$Fennec制药(FENC)$ 8-K Current report, items 1.01, 2.03, 3.02, 8.01, and 9.01 Accession Number: 0001558370-22-013838 Act: 34 Size: 759 KB 网页链接
$Fennec制药(FENC)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-22-013471 Act: 34 Size: 5 MB 网页链接
$Fennec制药(FENC)$ 8-K Current report, items 1.01, 2.03, 3.02, 8.01, and 9.01 Accession Number: 0001558370-22-011467 Act: 34 Size: 912 KB 网页链接
$Fennec制药(FENC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-22-080585 Size: 6 KB 网页链接